natgillin/translations-raw huggingface dataset:
• poor blood circulation disease (such as Raynaud's disease or Raynaud's syndrome)
• poremećaj krvotoka (kao što je Raynaudova bolest ili Raynaudov sindrom)
Timolol metabolism is mediated primarily by CYP2D6.
U metabolizmu timolola posreduje prvenstveno CYP2D6.
• tell your doctor before you have an operation that you are using AZARGA as timolol may change effects of some medicines used during anaesthesia.
• Prije kirurškog zahvata obavijestite svog liječnika da uzimate AZARGU jer timolol može promijeniti učinke nekih lijekova koji se koriste tijekom anestezije.
(predominantly in patients with preexisting bronchospastic disease), dyspnoea
(pretežno kod bolesnika s od ranije poznatim bronhospazmom), dispneja
Tiny amounts of hydrochloric acid and/or sodium hydroxide are added to keep acidity levels (pH levels) normal.
Male količine kloridne kiseline i/ili natrijeva hidroksida dodane su radi održavanja normalne kiselosti (vrijednosti pH).
AZARGA should be used with caution, in patients with mild/moderate chronic obstructive pulmonary disease (COPD) and only if the potential benefit outweighs the potential risk.
AZARGA se mora primijeniti s oprezom kod bolesnika s blagom/umjerenom kroničnom opstruktivnom plućnom bolešću (KOPB) i samo u slučaju da potencijalna korist nadmašuje potencijalni rizik.
Following administration of AZARGA, mean Cmax of timolol was reached at 0.79 ± 0.45 hours.
Pri primjeni AZARGE srednja Cmax timolola postignuta je za 0,79 ± 0,45 sati.
Brinzolamide is eliminated primarily by renal excretion (approximately 60%).
Brinzolamid se prvenstveno eliminira putem bubrega (približno 60%).
Do not stop using Azarga without speaking to your doctor first.
Ne prekidajte s primjenom AZARGE bez da ste se prije toga savjetovali sa Vašim liječnikom.
No specific drug interaction studies have been performed with AZARGA.
Nisu provedene posebne studije interakcije AZARGE s drugim lijekovima.
The possible role of brinzolamide on corneal endothelial function has not been investigated in patients with compromised corneas (particularly in patients with low endothelial cell count).
Moguća uloga brinzolamida na funkciju endotela rožnice nije ispitivana u bolesnika s kompromitiranom rožnicom (pogotovo u bolesnika s malim brojem endotelnih stanica).
The lower systemic exposure to timolol following AZARGA administration is not clinically relevant.
Manja sustavna izloženost timololu pri primjeni AZARGE nije klinički relevantna.
Timolol is absorbed into the systemic circulation.
Timolol se apsorbira u sustavnu cirkulaciju.
Alcon Cusí, S.A., Camil Fabra 58, 08320 El Masnou, Barcelona, Spain
Alcon Cusí, S.A., Camil Fabra 58, 08320 El Masnou, Barcelona, Španjolska
Brinzolamide is not an inhibitor of cytochrome P-450 isozymes.
Brinzolamid nije inhibitor izoenzima citokroma P-450.
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
Detaljne informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove http://www.ema.europa.eu.
Due to its negative effect on conduction time, beta-blockers should only be given with caution to patients with first degree heart block.
Zbog negativnog učinka na provođenje, beta-blokatori se smiju samo s oprezom primjenjivati kod bolesnika sa srčanim blokom prvog stupnja.
About 20% of the dose has been accounted for in urine as metabolite.
Oko 20% doze izlučuje se u urin u obliku metabolita.
This medicinal product should be used with caution in patients with risk of renal impairment because of the possible risk of metabolic acidosis.
Ovaj lijek mora se s oprezom primijeniti kod bolesnika s rizikom od oštećenja funkcije bubrega zbog mogućeg rizika metaboličke acidoze.
These findings occurred at doses that caused metabolic acidosis with decreased body weight gain in dams and decreased foetal weights.
Taj je nalaz dobiven pri dozama koje su prouzročile metaboličku acidozu, smanjeni prirast tjelesne težine u gravidnih ženki i smanjenu težinu fetusa.
3, bradycardia
3, bradikardija
• If you have now or have had in the past respiratory problems such as asthma, severe long lasting obstructive bronchitis (severe lung condition which may cause wheezing, difficulty in breathing and/or long standing cough) or other types of breathing problems.
• Ako sada imate poteškoća s disanjem ili ste ih imali u prošlosti, npr. astmu, teški dugotrajni opstruktivni bronhitis (teško stanje pluća koje može uzrokovati piskanje, otežano disanje i/ili dugotrajni kašalj) ili drugu vrstu poteškoća s disanjem.
• Ear: ringing in the ears, sensation of spinning or dizziness.
• Uho: zvonjava u ušima, osjećaj vrtnje ili omaglice.
• disturbances of heart rate such as slow heart beat
• poremećaje otkucaja srca kao što su usporeni otkucaji srca
However, at therapeutic doses of timolol in eye drops it is not likely that sufficient amounts would be present in breast milk to produce clinical symptoms of beta-blockade in the infant.
Ipak, kod terapijskih doza timolola u kapima za oko nije vjerojatna pojava dovoljne količine u majčinom mlijeku koja bi uzrokovala kliničke simptome betablokade kod dojenčeta.
You may experience a decreased heart rate, decreased blood pressure, heart failure, difficulty breathing and your nervous system may be affected
Može se pojaviti smanjeni broj otkucaja srca, sniženi krvni tlak, zatajenje srca, poteškoće s disanjem i može biti utjecaja na Vaš živčani sustav.
2, cerebrovascular accident syncope
2, cerebrovaskularni incident sinkopa
The effect on intra-ocular pressure or the known effects of systemic beta-blockade may be potentiated when timolol is given to the patients already receiving a systemic beta-blocking agent.
Učinak na intraokularni tlak ili poznati učinci sustavne beta-blokade mogu biti pojačani kada se timolol daje bolesnicima koji već primaju sustavni beta-blokator.
Common: punctate keratitis
Često: točkasti keratitis
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Unutar svake grupe učestalosti nuspojave su poredane u padajućem nizu prema stupnju ozbiljnosti.
One drop in the affected eye or eyes, twice a day.
Jedna kap u oko ili oči koje se liječe dvaput na dan.
• Hyperchloraemic acidosis (see section 4.2).
• Hiperkloremijska acidoza (vidjeti dio 4.2).
Eye drops, suspension
Kapi za oko, suspenzija
AZARGA has not been studied in patients with narrow-angle glaucoma and its use is not recommended in these patients.
AZARGA nije ispitivana u bolesnika s glaukomom uskog kuta i njena se primjena u tih bolesnika ne preporučuje.
Rare: insomnia Not known: depression
Rijetko: nesanica1 Nepoznato: depresija
Benzalkonium chloride has also been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy.
Zabilježeno je da benzalkonijev klorid uzrokuje točkastu keratopatiju i/ili toksičnu ulcerativnu keratopatiju.
Timolol is a non-selective adrenergic-blocking agent that has no intrinsic sympathomimetic, direct myocardial depressant or membrane-stabilising activity.
Timolol je neselektivni adrenergički blokator bez unutarnje simpatomimetičke aktivnosti, bez izravne depresijske aktivnosti na miokard i bez stabilizacijske aktivnosti na membrane.
One ml of suspension contains 0.10 mg benzalkonium chloride.
Jedan ml suspenzije sadrži 0,10 mg benzalkonijeva klorida.
• Severe allergic rhinitis
• Teški alergijski rinitis.
Only use AZARGA in both eyes if your doctor told you to. Take it for as long as your doctor told you to.
Kapajte AZARGU u oba oka samo ako Vas je tako uputio Vaš liječnik.
Since brinzolamide and its main metabolite are excreted predominantly by the kidney, AZARGA is therefore contraindicated in patients with severe renal impairment (see section 4.3).
Budući da se brinzolamid i njegov glavni metabolit pretežno izlučuju putem bubrega, AZARGA je kontraindicirana u bolesnika s teško oštećenom bubrežnom funkcijom (vidjeti dio 4.3).
It is expected that inhibitors of CYP3A4 such as ketoconazole, itraconazole, clotrimazole, ritonavir and troleandomycin will inhibit the metabolism of brinzolamide by CYP3A4.
Očekuje se da će inhibitori CYP3A4, poput ketokonazola, itrakonazola, klotrimazola, ritonavira i troleandomicina inhibirati metabolizam brinzolamida posredovan izoenzimom CYP3A4.
• Brinzolamide and timolol are absorbed systemically.
• Brinzolamid i timolol se apsorbiraju sustavno.
One of the active ingredients may impair the ability to perform tasks requiring mental alertness and/or physical coordination.
Jedan od djelatnih sastojaka može umanjiti sposobnost obavljanja zadataka koji zahtijevaju mentalnu budnost i/ili tjelesnu koordinaciju.
Instruct patients to keep the bottle tightly closed when not in use.
Bolesnika treba uputiti da bočicu čuva čvrsto zatvorenu kad nije u uporabi.
In a pharmacokinetic study, healthy subjects received oral brinzolamide (1 mg) twice daily for 2 weeks to shorten the time to reach steady-state prior to starting AZARGA administration.
U ispitivanju farmakokinetike zdravi su ispitanici peroralno primali brinzolamid (1 mg) dvaput na dan tijekom 2 tjedna, kako bi se skratilo vrijeme do postizanja stanja dinamičke ravnoteže prije početka primjene AZARGE.
Beta-blockers can mask the signs and symptoms of hypoglycaemia (see section 4.4).
Beta-blokatori mogu prikriti znakove i simptome hipoglikemije (vidjeti dio 4.4).
AZARGA can affect, or be affected by, other medicines you are taking, including other eye drops for the treatment of glaucoma.
AZARGA može utjecati na druge lijekove i drugi lijekovi mogu utjecati na AZARGU, uključujući druge kapi za oko koje uzimate za liječenje glaukoma.
Studies in animals have shown that following oral administration brinzolamide is excreted in breast milk, see section 5.3.
Ispitivanja na životinjama pokazala su da se nakon oralne primjene brinzolamid izlučuje u majčino mlijeko, vidjeti dio 5.3.
The use of two topical beta-adrenergic blocking agents or two local carbonic anhydrase inhibitors is not recommended (see section 4.5).
Lokalna primjena dva beta-adrenergička blokatora ili dva lokalna inhibitora karboanhidraze se ne preporučuje (vidjeti dio 4.5).
To reduce the systemic absorption, see section 4.2.
Da bi se smanjila sustavna apsorpcija, vidjeti dio 4.2.
Additional adverse reactions associated with the use of the individual components that may potentially occur with AZARGA are included in the table above.
Dodatne nuspojave povezane s primjenom svakog sastojka posebno, koje bi se mogle javiti i pri primjeni AZARGE, uključene su u tablicu iznad.
If signs of serious reactions or hypersensitivity occur, discontinue the use of this medicinal product.
Jave li se znakovi ozbiljnih reakcija ili preosjetljivosti, primjenu ovog lijeka treba prekinuti.
It is likely to be caused by passage of the eye drops in the nasopharynx via the nasolacrimal canal and is attributable to brinzolamide.
Vjerojatno je uzrokovana ulaskom kapi za oko u nazofarinks kroz nazolakrimalni kanal i može se pripisati brinzolamidu.
Respiratory reactions, including death due to bronchospasm in patients with asthma have been reported following administration of some ophthalmic beta-blockers.
Respiratorne reakcije, uključujući smrt zbog bronhospazma kod bolesnika s astmom, zabilježene su nakon lokalne primjene u oko nekih beta-blokatora.
• if you have dry eyes or cornea problems.
• Ako imate suho oko ili poteškoće s rožnicom.
Patients should be instructed to shake the bottle well before use.
Bolesnike se mora uputiti da bočicu dobro protresu prije primjene.
Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to patients with labile diabetes, as beta-blockers may mask the signs and symptoms of acute hypoglycaemia.
Beta-blokatori se moraju primjenjivati s oprezom kod bolesnika sklonih spontanoj hipoglikemiji ili bolesnika sa slabo reguliranom šećernom bolešću jer beta-blokatori mogu prikriti znakove i simptome akutne hipoglikemije.
Specifically, patients wearing contact lenses have not been studied and careful monitoring of these patients when using brinzolamide is recommended, since carbonic anhydrase inhibitors may affect corneal hydration.
Konkretno, nisu ispitivani bolesnici koji nose kontaktne leće te se preporučuje njihovo pozorno praćenje pri primjeni brinzolamida jer inhibitori karboanhidraze mogu utjecati na vlaženje rožnice.
In case of accidental ingestion, symptoms of overdose from beta blockade may include bradycardia, hypotension, cardiac failure and bronchospasm.
Kod slučajne ingestije, simptomi predoziranja beta-blokatorima mogu uključivati bradikardiju, hipotenziju, zatajenje srca i bronhospazam.
There is limited experience with AZARGA in the treatment of patients with pseudoexfoliative glaucoma or pigmentary glaucoma.
Iskustva s primjenom AZARGE u liječenju bolesnika s pseudoeksfolijativnim glaukomom ili pigmentnim glaukomom su ograničena.
AZARGA has not been studied in patients with severe renal impairment (creatinine clearance <30 ml/min) or in patients with hyperchloraemic acidosis (see section 4.3).
AZARGA nije ispitivana u bolesnika s teško oštećenom bubrežnom funkcijom (klirens kreatinina <30 ml/min), ni u onih s hiperkloremijskom acidozom (vidjeti dio 4.3).
Decrease of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction (see section 5.1).
Snižavanje intraokularnog tlaka (IOT) u odraslih bolesnika s glaukomom otvorenog kuta ili s očnom hipertenzijom u kojih se monoterapijom ne postiže dovoljno sniženje očnog tlaka (vidjeti dio 5.1).
Timolol and its metabolites are primarily excreted by the kidneys.
Timolol i njegovi metaboliti izlučuju se prvenstveno putem bubrega.
3, eye allergy
3, alergija oka
Not known: erectile dysfunction
Nepoznato: erektilna disfunkcija
AZARGA contains two active substances, brinzolamide and timolol, which work together to reduce pressure within the eye.
AZARGA sadrži dvije djelatne tvari brinzolamid i timolol, koje zajedno djeluju na snižavanje tlaka u oku.
The combined effect of these two active substances results in additional IOP reduction compared to either compound alone.
Kombiniranim učinkom tih dviju djelatnih tvari postiže se veće sniženje očnog tlaka nego svakom tvari posebno.
The non-inferiority of AZARGA as compared to dorzolamide 20 mg/ml + timolol 5 mg/ml in the mean IOP reduction was demonstrated across all time-points at all visits.
Neinferiornost AZARGE u usporedbi s dorzolamidom 20 mg/ml + timololom 5 mg/ml u snižavanju srednjeg očnog tlaka dokazana je u svim vremenskim točkama, pri svim kontrolnim posjetima.
Not known: myalgia
Nepoznato: mialgija
Beta-blockers are excreted in breast milk.
Beta blokatori se izlučuju u majčino mlijeko.
The metabolic pathways for the metabolism of brinzolamide involve N-dealkylation, O-dealkylation and oxidation of its N-propyl side chain.
Metabolički putovi brinzolamida uključuju N-dealkilaciju, O-dealkilaciju i oksidaciju njegovog N-propilnog bočnog lanca.
5 ml round opaque low density polyethylene bottles with a dispensing plug and white polypropylene screw cap (DROP-TAINER) containing 5 ml suspension.
Okrugle, neprozirne bočice od polietilena niske gustoće volumena 5 ml, s nastavkom za kapanje i bijelim polipropilenskim navojnim zatvaračem (DROP-TAINER) koje sadrže 5 ml suspenzije.
What you need to know before you use AZARGA
Što morate znati prije nego počnete primjenjivati AZARGU
At steady state, following administration of AZARGA, the mean plasma Cmax and AUC0-12h of timolol were 27% and 28% lower (Cmax: 0.824 ± 0.453 ng/ml; AUC0-12h: 4.71 ± 4.29 ng·h/ml), respectively, in comparison to the administration of timolol 5 mg/ml (Cmax: 1.13 ± 0.494 ng/ml; AUC0-12h: 6.58 ± 3.18 ng·h/ml).
U stanju dinamičke ravnoteže, nakon primjene AZARGE, srednja plazmatska Cmax timolola bila je 27% manja, a AUC0-12h 28% manja (Cmax: 0,824 ± 0,453 ng/ml; AUC0-12h: 4,71 ± 4,29 ng·h/ml) negoli pri primjeni timolola 5 mg/ml (Cmax: 1,13 ± 0,494 ng/ml; AUC0-12h: 6,58 ± 3,18 ng·h/ml).
Ocular tissue distribution data in rabbits showed that timolol can be measured in aqueous humour up to 48 hours after administration of AZARGA.
Podaci o distribuciji u tkivima oka kunića pokazuju da se timolol može u očnoj vodici mjeriti do 48 sati nakon primjene AZARGE.
AZARGA contains benzalkonium chloride
AZARGA sadrži benzalkonijev klorid
2, increases in the signs and symptoms of myasthenia gravis
2, pojačani znakovi i simptomi miastenije gravis pospanost
• If you are allergic to brinzolamide, medicines called sulphonamides (examples include medicines used to treat diabetes, infections and also diuretics (water tablets)), timolol, betablockers (medicines used to lower blood pressure or to treat heart disease) or any of the other ingredients of this medicine (listed in section 6).
• Ako ste alergični (preosjetljivi) na brinzolamid, lijekove koji se nazvaju sulfonamidi (primjeri uključuju lijekove za liječenje šećerne bolesti, infekcija te također diuretike (tablete za izmokravanje)), timolol, beta blokatore (lijekovi koji se koriste za snižavanje krvnog tlaka ili liječenje srčanih oboljenja) ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
• General side effects: difficulty sleeping (insomnia), throat pain, running nose
• Opće nuspojave: poteškoće sa spavanjem (nesanica), bol u grlu, curenje iz nosa
While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens and unresponsive to the usual doses of adrenaline used to treat anaphylactic reactions.
Pri uzimanju beta-blokatora može se dogoditi da bolesnici koji u anamnezi imaju atopiju ili tešku anafilaktičku reakciju na različite alergene mogu jače reagirati kod ponovljenog susreta s takvim alergenima i ne reagirati na uobičajene doze adrenalina koje se daju pri liječenju anafilaktičkih reakcija.
Plasma protein binding of brinzolamide is moderate (about 60%).
Brinzolamid se umjereno veže na proteine plazme (oko 60%).
1, memory loss
1, gubitak pamćenja
Overt cardiac failure, cardiogenic shock.
Manifestno zatajenje srca, kardiogeni šok.
Studies have shown that timolol does not dialyse readily.
Ispitivanja su pokazala da se timolol slabo uklanja dijalizom.
In patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal's angina and cardiac failure) and hypotension, therapy with beta-blockers should be critically assessed and the therapy with other active substances should be considered.
Kod bolesnika s kardiovaskularnim bolestima (npr. koronarna bolest srca, Prinzmetalova angina i zatajenje srca) i hipotenzijom, mora se kritički procijeniti uporabu terapije beta-blokatorima i uzeti u obzir terapiju s drugim djelatnim tvarima.
The concomitant administration of AZARGA and oral carbonic anhydrase inhibitors has not been studied and is not recommended (see section 4.5).
Istodobna primjena AZARGE i peroralno primjenjenih inhibitora karboanhidraze nije ispitivana i ne preporučuje se (vidjeti dio 4.5).
There are no adequate data regarding the use of ophthalmic brinzolamide and timolol in pregnant women.
Nema primjerenih podataka vezanih uz oftalmičku primjenu brinzolamida i timolola u trudnica.
CARTON FOR SINGLE BOTTLE 5 ml + CARTON FOR 3 x 5 ml BOTTLES
KUTIJA ZA JEDNU BOČICU 5 ml + KUTIJA ZA 3 BOČICE x 5 ml
When using nasolacrimal occlusion or closing the eyelids, the systemic absorption is reduced.
Primjenom nazolakrimalne okluzije ili zatvaranjem vjeđa smanjuje se sustavna apsorpcija.
• coronary heart disease (symptoms can include chest pain or tightness, breathlessness or choking), heart failure, low blood pressure
• koronarnu bolest srca (simptomi mogu uključivati bol u prsnom košu ili stezanje, nedostatak zraka ili gušenje), zatajenje srca, nizak krvni tlak,
Beta blockers can decrease the response to adrenaline used to treat anaphylactic reactions.
Beta-blokatori mogu smanjiti odgovor na adrenalin primijenjen u liječenju anafilaktičkih reakcija.
Non clinical data do not show any effects of either brinzolamide or timolol on male or female fertility following oral dosing.
Neklinički podaci ne upućuju na učinak niti brinzolamida niti timolola na plodnost kod muškaraca ili žena nakon peroralnog doziranja.
Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.
Mora se pratiti razina elektrolita u serumu (napose kalija) i pH krvi.
If you are worried, talk to your doctor or pharmacist.
Ako ste zabrinuti, porazgovarajte s liječnikom ili ljekarnikom.
Patients with cardiovascular diseases should be watched for signs of deterioration of these diseases and of adverse reactions.
Bolesnici s kardiovaskularnim bolestima moraju biti pod nadzorom zbog znakova pogoršanja bolesti ili pojave nuspojava.
• Hypersensitivity to sulphonamides (see section 4.4).
• Preosjetljivost na sulfonamide (vidjeti dio 4.4).
Following twice daily dosing of AZARGA for 13 weeks, red blood cell (RBC) concentrations of brinzolamide averaged 18.8  3.29 µM, 18.1  2.68 µM and 18.4  3.01 µM at weeks 4, 10 and 15, respectively, indicating that steady-state RBC concentrations of brinzolamide were maintained
Nakon primjene AZARGE dvaput na dan tijekom 13 tjedana, prosječna koncentracija brinzolamida u eritrocitima iznosila je 18,8  3,29 µM nakon 4 tjedna, 18,1  2,68 µM nakon 10 tjedana i 18,4  3,01 µM nakon 15 tjedana, što pokazuje da su se koncentracije brinzolamida u stanju dinamičke ravnoteže u eritrocitima održavale.
Systemic effects
Sustavni učinci
In three controlled clinical trials, the ocular discomfort upon instillation of AZARGA was significantly lower than that of dorzolamide 20 mg/ml + timolol 5 mg/ml.
U tri kontrolirana klinička istraživanja nelagodan osjećaj u oku nakon ukapavanja AZARGE bio je značajno slabiji negoli pri primjeni dorzolamida 20 mg/ml + timolola 5 mg/ml.
Careful monitoring of patients with compromised corneas, such as patients with diabetes mellitus or corneal dystrophies, is recommended.
Preporučuje se pozorno praćenje bolesnika s kompromitiranim rožnicama, kao što su bolesnici sa šećernom bolešću ili s distrofijom rožnice.
During lactation, the no adverse effect level in the offspring was 5 mg/kg/day.
Doza pri kojoj nije bilo štetnih učinaka u podmlatka tijekom dojenja iznosila je 5 mg/kg/dan.
• If you have a slow heart beat, heart failure or disorders of heart rhythm (irregular heartbeats).
• Ako imate usporene otkucaje srca, zatajenje srca ili srčanu aritmiju (nepravilne otkucaje srca).
(see section 4.4 Special warnings and precautions for use), keratopathy
Posebna upozorenja i mjere opreza pri uporabi), keratopatija
The drop will go in here (picture 1).
„prostor“ u koji se i ukapa kap lijeka (slika 1).
Developmental toxicity studies in rabbits with oral doses of brinzolamide of up to 6 mg/kg/day (214 times the recommended daily clinical dose of 28 µg/kg/day) revealed no effect on foetal development despite significant maternal toxicity.
Istraživanja razvojne toksičnosti u kunića pri peroralnim dozama brinzolamida do 6 mg/kg/dan (doza 214 puta veća od preporučene dnevne kliničke doze koja iznosi 28 µg/kg/dan) nisu pokazala učinak na fetalni razvoj, unatoč značajnoj toksičnosti za majku.
However, accumulation of brinzolamide is unlikely as renal elimination is the major route.
No nakupljanje brinzolamida nije vjerojatno jer je glavni način njegova uklanjanja putem bubrega.
Uncommon: decreased blood pressure Not known: hypotension
Manje često: sniženi krvni tlak Nepoznato: hipotenzija
Eye drops, suspension (eye drops)
Kapi za oko, suspenzija (kapi za oko)
• Blood: abnormal liver function values, increased blood chlorine levels, or decreased red blood cell count as seen in a blood test.
• Krv: poremećeni nalazi pretraga jetrene funkcije, povišene vrijednosti klora u krvi, smanjeni broj crvenih krvnih stanica uočen krvnom pretragom.
What AZARGA looks like and contents of the pack AZARGA is a liquid (white to off-white uniform suspension) supplied in a pack containing one 5 ml plastic bottle with a screw cap or in a pack containing three 5 ml bottles.
AZARGA je tekućina (jednolika suspenzija bijele do bjelkaste boje), dostupna u pakiranju koje sadrži jednu plastičnu bočicu od 5 ml s navojnim zatvaračem ili u pakiranju sa tri bočice od 5 ml.